KORU Medical Systems (KORU Medical Systems) Risk Assessment

View and export this data going back to 1996. Start your Free Trial

What is KORU Medical Systems Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of KORU Medical Systems is: High Risk: Sensitive to economic or industry trends.

Competitive Comparison of KORU Medical Systems's Risk Assessment

For the Medical Instruments & Supplies subindustry, KORU Medical Systems's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

KORU Medical Systems's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, KORU Medical Systems's Risk Assessment distribution charts can be found below:

* The bar in red indicates where KORU Medical Systems's Risk Assessment falls into.

KORU Medical Systems (NAS:KRMD) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

KORU Medical Systems Risk Assessment Related Terms

Thank you for viewing the detailed overview of KORU Medical Systems's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

KORU Medical Systems (KORU Medical Systems) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » KORU Medical Systems Inc (NAS:KRMD) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Corporate Drive, Mahwah, NJ, USA, 07430

Website

https://www.korumedical.com

KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on home and specialty infusion solutions. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Executives

Manko Joseph M. Jr.	10 percent owner	1717 ARCH STREET, 37TH FLOOR, PHILADELPHIA PA 19103
Kenneth E Miller	officer: Chief Commercial Officer	26 MOUNTAINVIEW RD, WARREN NJ 07059
Edward Wholihan	director	C/O ALLENA PHARMACEUTICALS, INC., ONE NEWTOWN EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Linda M Tharby	officer: President and CEO	BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Robert Cascella	director	C/O HOLOGIC, INC., BEDFORD MA 01730
Lafrence Andrew D.c.	officer: Chief Financial Officer	C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Thomas Edward Adams	officer: Interim CFO	524 WOODLAND AVENUE, BRIELLE NJ 08730
Brian Case	officer: Chief Technology Officer	424 CYPRUS CIR, LAKE VILLA IL 60046-8629
Shahriar Matin	director	96 TALAMINE COURT, COLORADO SPRINGS CO 80907
Donna French	director	25 SEARSVILLE COURT, HILLSBOROUGH CA 94010
Donald B Pettigrew	officer: Pres./Chief Commercial Officer	7871 ENGEN LOOP, PARK CITY UT 84098
Karen Fisher	officer: CFO	24 CARPENTER ROAD, CHESTER NY 10918
Daniel S Goldberger	director	24 CARPENTER ROAD, CHESTER NY 10918
R John Fletcher	director	C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Horton Freedom, L.p.	10 percent owner	1717 ARCH STREET, 37TH FLOOR, PHILADELPHIA PA 19103